Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Liver Diseases

  Free Subscription


Articles published in J Hepatol

Retrieve available abstracts of 280 articles:
HTML format
Text format



Single Articles


    November 2018
  1. STAMM LM, Brainard DM, McHutchison JG
    Sofosbuvir/Velpatasvir for Patients with Chronic Genotype 3 HCV Infection with Compensated Cirrhosis: Response to EASL Recommendations on Treatment of Hepatitis C 2018.
    J Hepatol. 2018 Nov 13. pii: S0168-8278(18)32528.
    PubMed     Text format    



  2. Reply to: "Sofosbuvir/Velpatasvir for Patients with Chronic Genotype 3 HCV Infection with Compensated Cirrhosis: Response to EASL Recommendations on Treatment of Hepatitis C 2018".
    J Hepatol. 2018 Nov 12. pii: S0168-8278(18)32529.
    PubMed     Text format    


  3. OTETE H, Deleuran T, Fleming KM, Card T, et al
    Reply to: "Hip fracture risk in patients with alcoholic cirrhosis: Do comorbidities and complications matter?"
    J Hepatol. 2018 Nov 10. pii: S0168-8278(18)32459.
    PubMed     Text format    


  4. YU SJ, Ma C, Heinrich B, Brown ZJ, et al
    Targeting the crosstalk between cytokine-induced killer cells and myeloid-derived suppressor cells in hepatocellular carcinoma.
    J Hepatol. 2018 Nov 8. pii: S0168-8278(18)32525.
    PubMed     Text format     Abstract available


  5. WEISS N, Housset C, Thabut D
    Hepatic encephalopathy: Another brick in the wall.
    J Hepatol. 2018 Nov 7. pii: S0168-8278(18)32499.
    PubMed     Text format    


  6. FERNANDEZ J, Prado V, Trebicka J, Amoros A, et al
    Multidrug-resistant bacterial infections in patients with decompensated cirrhosis and with acute-on-chronic liver failure in Europe.
    J Hepatol. 2018 Nov 1. pii: S0168-8278(18)32511.
    PubMed     Text format     Abstract available


    October 2018
  7. RAVEN A, Forbes SJ
    Hepatic progenitors in liver regeneration.
    J Hepatol. 2018 Oct 31. pii: S0168-8278(18)30154.
    PubMed     Text format    


  8. ZHAO LY, Luo YJ, Zhu J, Liu HY, et al
    Hip fracture risk in patients with alcoholic cirrhosis: Do comorbidities and complications matter?
    J Hepatol. 2018 Oct 31. pii: S0168-8278(18)32386.
    PubMed     Text format    


  9. METWALLY M, Bayoumi A, Romero-Gomez M, Thabet K, et al
    A polymorphism in the Irisin-encoding gene (FNDC5) associates with hepatic steatosis by differential miRNA binding to the 3'UTR.
    J Hepatol. 2018 Oct 30. pii: S0168-8278(18)32505.
    PubMed     Text format     Abstract available


  10. MARASCO G, Colecchia A, Colli A, Ravaioli F, et al
    Role of liver and spleen stiffness in predicting the recurrence of hepatocellular carcinoma after resection.
    J Hepatol. 2018 Oct 30. pii: S0168-8278(18)32506.
    PubMed     Text format     Abstract available


  11. KIM HY, So YH, Kim W, Ahn DW, et al
    Noninvasive Response Prediction in Prophylactic Carvedilol Therapy for Cirrhotic Patients with Esophageal Varices.
    J Hepatol. 2018 Oct 30. pii: S0168-8278(18)32502.
    PubMed     Text format     Abstract available


  12. YIP TC, Wong GL, Chan HL, Tse YK, et al
    HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues.
    J Hepatol. 2018 Oct 24. pii: S0168-8278(18)32497.
    PubMed     Text format     Abstract available


  13. IOANNOU GN
    Reply to: "Individual surveillance using model-based hepatocellular carcinoma risk estimates in chronic hepatitis C patients after antiviral treatment".
    J Hepatol. 2018 Oct 19. pii: S0168-8278(18)32445.
    PubMed     Text format    


  14. JI F, Yeo YH, He C, Li J, et al
    Individual surveillance using model-based hepatocellular carcinoma risk estimates in chronic hepatitis C patients after antiviral treatment.
    J Hepatol. 2018 Oct 15. pii: S0168-8278(18)32390.
    PubMed     Text format    


  15. D'AMICO G, Bataller R
    Need for surveillance of hepatocellular carcinoma in patients with alcoholic cirrhosis.
    J Hepatol. 2018 Oct 11. pii: S0168-8278(18)32447.
    PubMed     Text format    


  16. O'BRIEN A, Kamath PS, Trotter J
    MACHT - Outpatient albumin infusions do not prevent complications of cirrhosis in patients on the liver transplant waiting list.
    J Hepatol. 2018 Oct 9. pii: S0168-8278(18)32444.
    PubMed     Text format    


  17. JAYAKUMAR S, Middleton MS, Lawitz EJ, Mantry PS, et al
    Longitudinal Correlations Between MRE, MRI-PDFF, and Liver Histology in Patients with Nonalcoholic Steatohepatitis: Analysis of Data from a Phase 2 Trial of Selonsertib.
    J Hepatol. 2018 Oct 3. pii: S0168-8278(18)32443.
    PubMed     Text format     Abstract available


  18. GIANNINI EG, Bodini G, Furnari M, Marabotto E, et al
    NASH-related and cryptogenic cirrhosis similarities extend beyond cirrhosis.
    J Hepatol. 2018;69:972-973.
    PubMed     Text format    


  19. DE FRANCHIS R, Krag A
    Ruling out esophageal varices in NAFLD cirrhosis: Can we do without endoscopy?
    J Hepatol. 2018;69:769-771.
    PubMed     Text format    


  20. CHEN Y, Chen HN, Wang K, Zhang L, et al
    Ketoconazole exacerbates mitophagy to induce apoptosis by downregulating cyclooxygenase-2 in hepatocellular carcinoma.
    J Hepatol. 2018 Oct 1. pii: S0168-8278(18)32441.
    PubMed     Text format     Abstract available


  21. SAGGI H, Maitra D, Jiang A, Zhang R, et al
    Loss of hepatocyte beta-Catenin protects mice from experimental porphyria-associated liver injury.
    J Hepatol. 2018 Oct 1. pii: S0168-8278(18)32442.
    PubMed     Text format     Abstract available


    September 2018
  22. DEUGNIER Y, Morcet J, Laine F, Hamdi-Roze H, et al
    Reduced phenotypic expression in genetic hemochromatosis with time: role of exposure to nongenetic modifiers.
    J Hepatol. 2018 Sep 20. pii: S0168-8278(18)32383.
    PubMed     Text format     Abstract available


  23. LOW JTS, Rohde G, Pittordou K, Candy B, et al
    Supportive and palliative care in people with cirrhosis: international systematic review of the perspective of patients, family members and health professionals.
    J Hepatol. 2018 Sep 19. pii: S0168-8278(18)32381.
    PubMed     Text format     Abstract available


  24. KIM Y, Kang K, Lee SB, Seo D, et al
    Small molecule-mediated reprogramming of human hepatocytes into bipotent progenitor cells.
    J Hepatol. 2018 Sep 18. pii: S0168-8278(18)32380.
    PubMed     Text format     Abstract available


  25. CHAN AWH, Zhong J, Berhane S, Toyoda H, et al
    Development of pre and post-operative models to predict early recurrence of hepatocellular carcinoma after surgical resection.
    J Hepatol. 2018 Sep 17. pii: S0168-8278(18)32378.
    PubMed     Text format     Abstract available


  26. ZHANG T, Hu J, Wang X, Zhao X, et al
    MicroRNA-378 Promotes Hepatic Inflammation and Fibrosis via Modulation of the NFkappaB-TNFalpha Pathway.
    J Hepatol. 2018 Sep 12. pii: S0168-8278(18)32376.
    PubMed     Text format     Abstract available


  27. CALDERARO J, Petitprez F, Becht E, Laurent A, et al
    Intra-tumoral tertiary lymphoid structures are associated with a low risk of early recurrence of hepatocellular carcinoma.
    J Hepatol. 2018 Sep 10. pii: S0168-8278(18)32373.
    PubMed     Text format     Abstract available


  28. TORGERSON PR, Schweiger A, Deplazes P, Pohar M, et al
    Corrigendum to "Alveolar echinococcosis: From a deadly disease to a well-controlled infection. Relative survival and economic analysis in Switzerland over the last 35years" [J Hepatol 49 (2008) 72-77].
    J Hepatol. 2018 Sep 8. pii: S0168-8278(18)32292.
    PubMed     Text format    


  29. SHEARER J, Chizhande D, Jones R, Rowe IA, et al
    Non-invasive prediction of oesophageal varices in patients with cirrhosis secondary to non-alcoholic fatty liver disease.
    J Hepatol. 2018 Sep 8. pii: S0168-8278(18)32282.
    PubMed     Text format    


  30. HADJIHAMBI A, Harrison IF, Costas-Rodriguez M, Vanhaecke F, et al
    Impaired brain glymphatic flow in experimental hepatic encephalopathy.
    J Hepatol. 2018 Sep 7. pii: S0168-8278(18)32367.
    PubMed     Text format     Abstract available


  31. GUSTOT T, Moreau R
    Acute-on-Chronic Liver Failure vs. Traditional Acute Decompensation of Cirrhosis.
    J Hepatol. 2018 Sep 6. pii: S0168-8278(18)32370.
    PubMed     Text format     Abstract available


  32. PETTA S, Sebastiani G, de Ledinghen V
    Reply to: "Non-invasive prediction of oesophageal varices in patients with cirrhosis secondary to non-alcoholic fatty liver disease".
    J Hepatol. 2018 Sep 4. pii: S0168-8278(18)32300.
    PubMed     Text format    


  33. GJORGJIEVA M, Calderaro J, Monteillet L, Silva M, et al
    Dietary exacerbation of metabolic stress leads to accelerated hepatic carcinogenesis in glycogen storage disease type Ia.
    J Hepatol. 2018 Sep 4. pii: S0168-8278(18)32271.
    PubMed     Text format     Abstract available


  34. MERLI M, Durand F
    Muscle mass vs. adipose tissue to predict outcome in cirrhosis: Which matters and in which patients?
    J Hepatol. 2018;69:567-569.
    PubMed     Text format    


    August 2018

  35. Corrigendum to "EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis" [J Hepatol 69 (2018) 406-460].
    J Hepatol. 2018 Aug 29. pii: S0168-8278(18)32290.
    PubMed     Text format    


  36. YOUNOSSI Z, Stepanova M, Sanyal AJ, Harrison SA, et al
    The Conundrum of Cryptogenic Cirrhosis: Adverse Outcomes without Treatment Options.
    J Hepatol. 2018 Aug 22. pii: S0168-8278(18)32295.
    PubMed     Text format     Abstract available


  37. MOREAU R, Bataller R, Berg T, Lotersztajn S, et al
    Corrigendum to "From the Editor's Desk August 2018" [J Hepatol 69 (2018) 265-268].
    J Hepatol. 2018 Aug 21. pii: S0168-8278(18)32281.
    PubMed     Text format    


  38. ANDRADE F, Shukla A, Bureau C, Senzolo M, et al
    Pregnancy in Idiopathic Non-Cirrhotic Portal Hypertension: A Multicentric Study on Maternal and Fetal Management and Outcome.
    J Hepatol. 2018 Aug 20. pii: S0168-8278(18)32286.
    PubMed     Text format     Abstract available


  39. CLARK VC, Marek G, Liu C, Collinsworth A, et al
    Clinical and Histologic Features of Adults with Alpha-1 Antitrypsin Deficiency in a Non-Cirrhotic Cohort.
    J Hepatol. 2018 Aug 20. pii: S0168-8278(18)32284.
    PubMed     Text format     Abstract available


  40. IOANNOU GN, Green PK, Beste LA, Mun EJ, et al
    Development of Models Estimating the Risk of Hepatocellular Carcinoma After Antiviral Treatment for Hepatitis C.
    J Hepatol. 2018 Aug 20. pii: S0168-8278(18)32287.
    PubMed     Text format     Abstract available


  41. SOLA E, Sole C, Simon-Talero M, Martin-Llahi M, et al
    MIDODRINE &ALBUMIN for Preventing COMPLICATIONS IN PATIENTS WITH CIRRHOSIS AWAITING Liver transplantation.
    J Hepatol. 2018 Aug 20. pii: S0168-8278(18)32285.
    PubMed     Text format     Abstract available


  42. BRUIX J, Cheng AL, Meinhardt G, Nakajima K, et al
    Corrigendum to "Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies" [J hepatol 67 (2017) 999-1008].
    J Hepatol. 2018 Aug 10. pii: S0168-8278(18)32269.
    PubMed     Text format    


  43. ASRANI SK, Saracino G, O'Leary JG, Gonzalez S, et al
    Corrigendum to "Recipient characteristics and morbidity and mortality after liver transplantation" [J hepatol 69 (2018) 43-50].
    J Hepatol. 2018 Aug 7. pii: S0168-8278(18)32268.
    PubMed     Text format    


  44. YANG X, Chen J, Wang N, Liu Z, et al
    Clinical use of dendritic cell-derived exosomes for hepatocellular carcinoma immunotherapy: How far we are?
    J Hepatol. 2018 Aug 6. pii: S0168-8278(18)32183.
    PubMed     Text format    


  45. GANNE-CARRIE N, Chaffaut C, Bourcier V, Archambeaud I, et al
    Estimate of hepatocellular carcinoma's incidence in patients with alcoholic cirrhosis.
    J Hepatol. 2018 Aug 6. pii: S0168-8278(18)32278.
    PubMed     Text format     Abstract available


  46. TSUCHIDA T, Lee YA, Fujiwara N, Ybanez M, et al
    Corrigendum to "A simple diet- and chemical-induced murine NASH model with rapid progression of steatohepatitis, fibrosis and liver cancer" [J Hepatol 69 (2018) 385-395].
    J Hepatol. 2018 Aug 3. pii: S0168-8278(18)32263.
    PubMed     Text format    


    July 2018
  47. KIM JH, Kim YD, Lee M, Jun BG, et al
    Modified PAGE-B score predicts the risk of hepatocellular carcinoma in Asians with chronic hepatitis B on antiviral therapy.
    J Hepatol. 2018 Jul 31. pii: S0168-8278(18)32274.
    PubMed     Text format     Abstract available


  48. MAROT A, Henrion J, Knebel JF, Deltenre P, et al
    Individualized prediction of hepatocellular carcinoma occurrence in a large cohort of patients with cirrhosis.
    J Hepatol. 2018 Jul 23. pii: S0168-8278(18)32160.
    PubMed     Text format    


  49. AJI T, Dong JH, Shao YM, Zhao JM, et al
    Ex vivo Liver Resection and Autotransplantation as Alternative to Allotransplantation for End-stage Hepatic Alveolar Echinococcosis.
    J Hepatol. 2018 Jul 19. pii: S0168-8278(18)32258.
    PubMed     Text format     Abstract available


  50. SCOTT CL, Guilliams M
    The role of Kupffer cells in hepatic iron and lipid metabolism.
    J Hepatol. 2018 Jul 9. pii: S0168-8278(18)30130.
    PubMed     Text format    


  51. THULUVATH PJ, Kantsevoy S, Thuluvath AJ, Savva Y, et al
    Reply to: "NASH-related and cryptogenic cirrhosis similarities extend beyond cirrhosis": Cryptogenic cirrhosis should not be equated with NASH cirrhosis based on UNOS data mining and Bayesian 'doctrine of chances'.
    J Hepatol. 2018 Jul 5. pii: S0168-8278(18)32168.
    PubMed     Text format    


  52. PLOTON M, Mazuy C, Gheeraert C, Dubois V, et al
    The Nuclear Bile Acid Receptor FXR is a PKA- and FOXA2-Sensitive Activator of Fasting Hepatic Gluconeogenesis.
    J Hepatol. 2018 Jul 4. pii: S0168-8278(18)32175.
    PubMed     Text format     Abstract available


  53. LAI SW, Lin CL, Liao KF
    Association between cirrhosis and hip fracture in older people in a population-based cohort study.
    J Hepatol. 2018 Jul 2. pii: S0168-8278(18)32060.
    PubMed     Text format    


    June 2018
  54. TANDON P, Ismond KP, Riess K, Duarte-Rojo A, et al
    Exercise in Cirrhosis: Translating evidence and experience to practice.
    J Hepatol. 2018 Jun 28. pii: S0168-8278(18)32170.
    PubMed     Text format     Abstract available


  55. FUHRMANN V, Krowka M
    Hepatopulmonary syndrome.
    J Hepatol. 2018 Jun 27. pii: S0168-8278(18)30007.
    PubMed     Text format    


  56. QIN JJ, Mao W, Wang X, Sun P, et al
    Caspase recruitment domain 6 protects against hepatic ischemia/reperfusion injury by suppressing ASK1.
    J Hepatol. 2018 Jun 26. pii: S0168-8278(18)32167.
    PubMed     Text format     Abstract available


  57. YU JJ, Li JD, Xu XF, Shen F, et al
    Is obesity a risk factor for the development of acute on chronic liver failure in patients with decompensated cirrhosis?
    J Hepatol. 2018 Jun 8. pii: S0168-8278(18)32061.
    PubMed     Text format    


  58. BRADLEY CR, Cox EF, Scott RA, James MW, et al
    Multi organ assessment of Compensated Cirrhosis Patients using quantitative Magnetic Resonance Imaging.
    J Hepatol. 2018 Jun 7. pii: S0168-8278(18)32122.
    PubMed     Text format     Abstract available


  59. TONG M, Che N, Zhou L, Luk ST, et al
    Efficacy of annexin A3 blockade in sensitizing hepatocellular carcinoma to sorafenib and regorafenib.
    J Hepatol. 2018 Jun 6. pii: S0168-8278(18)32119.
    PubMed     Text format     Abstract available


  60. SEGERITZ CP, Rashid ST, Cardoso de Brito M, Paola MS, et al
    hiPSC hepatocyte model demonstrates the role of unfolded protein response and inflammatory networks in alpha1-antitrypsin deficiency.
    J Hepatol. 2018 Jun 4. pii: S0168-8278(18)32113.
    PubMed     Text format     Abstract available


  61. TURCO L, Garcia-Tsao G, Rossi R, Villa E, et al
    Reply to "The Relationship of Hyperdynamic Circulation and Cardiodynamic States in Cirrhosis".
    J Hepatol. 2018 Jun 2. pii: S0168-8278(18)32101.
    PubMed     Text format    


  62. NAKAMURA K, Zhang M, Kageyama S, Ke B, et al
    Protective effects of heme oxygenase 1 during ischemia r epefrfsuion injury: Hepatocytes or non parenchymal cells?
    J Hepatol. 2018 Jun 2. pii: S0168-8278(18)32114.
    PubMed     Text format    


  63. LEE S, Kang TW
    Reply to "Influence of ablation technique on treatment failure for perivascular hepatocellular carcinoma".
    J Hepatol. 2018 Jun 2. pii: S0168-8278(18)32117.
    PubMed     Text format    


    May 2018
  64. SUNDARAM V, Goldberg DS, Jalan R
    Author response: Is obesity a risk factor for the development of acute on chronic liver failure in patients with decompensated cirrhosis?
    J Hepatol. 2018 May 31. pii: S0168-8278(18)32100.
    PubMed     Text format    


  65. MOHKAM K, Rode A, Mabrut JY
    Influence of ablation technique on treatment failure for perivascular hepatocellular carcinoma.
    J Hepatol. 2018 May 25. pii: S0168-8278(18)32045.
    PubMed     Text format    


  66. PETTA S, Sebastiani G, Bugianesi E, Vigano M, et al
    Noninvasive Prediction of Esophageal Varices by Stiffness and Platelet in Nonalcoholic Fatty Liver Disease Cirrhosis.
    J Hepatol. 2018 May 23. pii: S0168-8278(18)32065.
    PubMed     Text format     Abstract available


  67. LE GUILCHER C, Garcin I, Dellis O, Cauchois F, et al
    The P2X4 purinergic receptor regulates hepatic myofibroblast activation during liver fibrogenesis.
    J Hepatol. 2018 May 23. pii: S0168-8278(18)32066.
    PubMed     Text format     Abstract available


  68. ALVARADO E, Garcia-Guix M, Mirabet S, Villanueva C, et al
    The relationship of hyperdynamic circulation and cardiodynamic states in cirrhosis.
    J Hepatol. 2018 May 18. pii: S0168-8278(18)32044.
    PubMed     Text format    


  69. XU D, Xu M, Kong X, Xia Q, et al
    Protective effects of heme oxygenase 1 during ischemia-reperfusion injury: Hepatocytes or non-parenchymal cells?
    J Hepatol. 2018 May 17. pii: S0168-8278(18)32046.
    PubMed     Text format    


  70. NOORDZIJ W, de Jong KP, de Meijer VE
    Response to: Positron emission tomography/computed tomography with (18)F-fluorocholine improve tumor staging and treatment allocation in patients with hepatocellular carcinoma.
    J Hepatol. 2018 May 17. pii: S0168-8278(18)32024.
    PubMed     Text format    


  71. BANERJEE R, Kelly M, Wilman H, Wright T, et al
    Imaging endpoints for non-alcoholic steatohepatitis (NASH) therapeutic trials: A growing role for multiparametric MRI?
    J Hepatol. 2018 May 16. pii: S0168-8278(18)32033.
    PubMed     Text format    


  72. SUAREZ-AMARAN L, Usai C, Di Scala M, Godoy C, et al
    Erratum to "A new HDV mouse model identifies mitochondrial antiviral signaling protein (MAVS) as a key player in IFN-beta induction" [J Hepatol 67 (2017) 669-679].
    J Hepatol. 2018 May 15. pii: S0168-8278(18)32010.
    PubMed     Text format    


  73. PATNAIK MM, Kamath PS, Simonetto DA
    Grand Rounds: Hepatic Manifestations of Telomere Biology Disorders.
    J Hepatol. 2018 May 11. pii: S0168-8278(18)32052.
    PubMed     Text format     Abstract available


  74. WONG GL, Chan HL, Tse YK, Yip TC, et al
    Normal on-treatment ALT during antiviral treatment is associated with a lower risk of hepatic events in patients with chronic hepatitis B.
    J Hepatol. 2018 May 11. pii: S0168-8278(18)32055.
    PubMed     Text format     Abstract available


  75. ORRU C, Szydlowska M, Taguchi K, Zavattari P, et al
    Genetic inactivation of Nrf2 prevents clonal expansion of initiated cells in a nutritional model of rat hepatocarcinogenesis.
    J Hepatol. 2018 May 11. pii: S0168-8278(18)32056.
    PubMed     Text format     Abstract available


  76. OH SH, Swiderska-Syn M, Jewell ML, Premont RT, et al
    Liver regeneration requires Yap1-TGFbeta-dependent epithelial-mesenchymal transition in hepatocytes.
    J Hepatol. 2018 May 11. pii: S0168-8278(18)32054.
    PubMed     Text format     Abstract available


    April 2018
  77. CHALAYE J, Costentin CE, Luciani A, Nault JC, et al
    Reply to "PET/CT with 18F-fluorocholine improve tumor staging and treatment allocation in patients with hepatocellular carcinoma".
    J Hepatol. 2018 Apr 29. pii: S0168-8278(18)32031.
    PubMed     Text format    


  78. MOLLER S, Lee SS
    Cirrhotic cardiomyopathy.
    J Hepatol. 2018 Apr 28. pii: S0168-8278(18)30017.
    PubMed     Text format    


  79. EBADI M, Tandon P, Moctezuma-Velazquez C, Ghosh S, et al
    Low Subcutaneous Adiposity Associates with Higher Mortality in Female Patients with Cirrhosis.
    J Hepatol. 2018 Apr 27. pii: S0168-8278(18)32026.
    PubMed     Text format     Abstract available


  80. SUNDARAM V, Jalan R, Ahn JC, Charlton MR, et al
    Class III obesity is a risk factor for the development of acute on chronic liver failure in patients with decompensated cirrhosis.
    J Hepatol. 2018 Apr 27. pii: S0168-8278(18)32027.
    PubMed     Text format     Abstract available


  81. ZHAO L, Zhang C, Luo X, Wang P, et al
    CD36 palmitoylation disrupts free fatty acid metabolism and promotes tissue inflammation in non-alcoholic steatohepatitis.
    J Hepatol. 2018 Apr 26. pii: S0168-8278(18)32014.
    PubMed     Text format     Abstract available


  82. SPOSITO C, Spreafico C, Mazzaferro V
    Re: validation of response to yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasion.
    J Hepatol. 2018 Apr 26. pii: S0168-8278(18)32016.
    PubMed     Text format    


  83. OTETE H, Deleuran T, Fleming KM, Card TR, et al
    Hip fracture risk in patients with alcoholic cirrhosis: a population-based study using English and Danish data.
    J Hepatol. 2018 Apr 16. pii: S0168-8278(18)31978.
    PubMed     Text format     Abstract available


  84. WIEST R, Albillos A, Trauner M, Bajaj JS, et al
    Corrigendum to "Targeting the gut-liver axis in liver disease" [J Hepatol 67 (2017) 1084-1103].
    J Hepatol. 2018 Apr 11. pii: S0168-8278(18)30149.
    PubMed     Text format    



  85. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis.
    J Hepatol. 2018 Apr 10. pii: S0168-8278(18)31966.
    PubMed     Text format    



  86. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma.
    J Hepatol. 2018 Apr 5. pii: S0168-8278(18)30215.
    PubMed     Text format    


  87. LUCIDI C, Lattanzi B, Riggio O, Merli M, et al
    May sarcopenia and/or hepatic encephalopathy improve the predictivity of model for end-stage liver disease?
    J Hepatol. 2018 Apr 4. pii: S0168-8278(18)30213.
    PubMed     Text format    


  88. VAN VUGT JLA, Alferink LJM, Buettner S, Metselaar HJ, et al
    Reply to: "May sarcopenia and/or hepatic encephalopathy improve the predictivity of model for end-stage liver disease?" and "Has the time come for using MELD-Sarcopenia score?"
    J Hepatol. 2018 Apr 3. pii: S0168-8278(18)30212.
    PubMed     Text format    


  89. BAJAJ JS
    Hepatic encephalopathy: classification and treatment.
    J Hepatol. 2018;68:838-839.
    PubMed     Text format    


    March 2018
  90. TSUCHIDA T, Lee YA, Fujiwara N, Ybanez M, et al
    A Simple Diet- and Chemical-Induced Murine NASH Model with Rapid Progression of Steatohepatitis, Fibrosis and Liver Cancer.
    J Hepatol. 2018 Mar 20. pii: S0168-8278(18)30175.
    PubMed     Text format     Abstract available


  91. TURNER AM, Stolk J, Bals R, Lickliter J, et al
    Hepatic-targeted RNA interference provides persistent knockdown of alpha-1 antitrypsin levels in ZZ patients.
    J Hepatol. 2018 Mar 20. pii: S0168-8278(18)30176.
    PubMed     Text format     Abstract available


  92. KONERMAN MA, Jones JC, Harrison SA
    Corrigendum to "Pharmacotherapy for NASH: Current and emerging" [J Hepatol 68 (2017) 362-375].
    J Hepatol. 2018 Mar 19. pii: S0168-8278(18)30150.
    PubMed     Text format    


  93. PEREYRA D, Starlinger P
    Intra Platelet Serotonin Affects Overall Survival in Hepatocellular Cancer Patients.
    J Hepatol. 2018 Mar 15. pii: S0168-8278(18)30166.
    PubMed     Text format    


  94. HSU YC, Cheuk-Fung Yip T, Ho HJ, Wai-Sun Wong V, et al
    Development of a scoring system to Predict Hepatocellular Carcinoma in Asians on Antivirals for Chronic Hepatitis B.
    J Hepatol. 2018 Mar 15. pii: S0168-8278(18)30170.
    PubMed     Text format     Abstract available


  95. ROMANO A, Angeli P, Piovesan S, Noventa F, et al
    "Newly diagnosed Hepatocellular Carcinoma in patients with advanced hepatitis C treated with DAAs: a prospective population study".
    J Hepatol. 2018 Mar 15. pii: S0168-8278(18)30172.
    PubMed     Text format     Abstract available


  96. PUOTI M, Foster GR, Wang S, Mutimer D, et al
    High SVR12 with 8-week and 12-week Glecaprevir/Pibrentasvir: Integrated Analysis of HCV Genotype 1-6 Patients Without Cirrhosis.
    J Hepatol. 2018 Mar 15. pii: S0168-8278(18)30165.
    PubMed     Text format     Abstract available


  97. DONG LQ, Shi Y, Ma LJ, Yang LX, et al
    Spatial and temporal clonal evolution of intrahepatic cholangiocarcinoma.
    J Hepatol. 2018 Mar 15. pii: S0168-8278(18)30167.
    PubMed     Text format     Abstract available


  98. MOSCONI C, Cucchetti A, Pettinato C, Golfieri R, et al
    Validation of response to yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasion.
    J Hepatol. 2018 Mar 13. pii: S0168-8278(18)30151.
    PubMed     Text format    


  99. ABITBOL S, Dahmani R, Coulouarn C, Ragazzon B, et al
    AXIN deficiency in human and mouse hepatocytes induces hepatocellular carcinoma in the absence of beta-catenin activation.
    J Hepatol. 2018 Mar 7. pii: S0168-8278(17)32534.
    PubMed     Text format     Abstract available


  100. LEE S, Kang TW, Cha DI, Song KD, et al
    Radiofrequency ablation versus surgery for perivascular hepatocellular carcinoma: propensity score analyses of long-term outcomes.
    J Hepatol. 2018 Mar 7. pii: S0168-8278(18)30148.
    PubMed     Text format     Abstract available


  101. ZHANG Z, Filzmayer C, Ni Y, Sultmann H, et al
    Hepatitis D Virus replication is sensed by MDA5 and induces IFN-beta/lambda responses in hepatocytes.
    J Hepatol. 2018 Mar 7. pii: S0168-8278(18)30143.
    PubMed     Text format     Abstract available


  102. CHALAYE J, Costentin CE, Luciani A, Amaddeo G, et al
    Positron emission tomography / computed tomography with 18F-fluorocholine improve tumor staging and treatment allocation in patients with hepatocellular carcinoma.
    J Hepatol. 2018 Mar 5. pii: S0168-8278(18)30136.
    PubMed     Text format     Abstract available


  103. LIU JJ, Li Y, Chen WS, Liang Y, et al
    Shp2 Deletion in Hepatocytes Suppresses Hepatocarcinogenesis Driven by Oncogenic beta-Catenin, PIK3CA and MET.
    J Hepatol. 2018 Mar 2. pii: S0168-8278(18)30131.
    PubMed     Text format     Abstract available


  104. NAULT JC, Galle PR, Marquardt JU
    The role of molecular enrichment on future therapies in hepatocellular carcinoma.
    J Hepatol. 2018 Mar 2. pii: S0168-8278(18)30134.
    PubMed     Text format     Abstract available


  105. KARLSEN TH, Tacke F
    <<The times they are a'changin'>> - Positioning the European Association for the Study of the Liver in the changing landscape of hepatology.
    J Hepatol. 2018 Mar 1. pii: S0168-8278(18)30112.
    PubMed     Text format    


    February 2018
  106. SHA M, Jeong S, Xia Q
    Antiviral Therapy Improves Survival in patients with HBV infection and Intrahepatic Cholangiocarcinoma undergoing Liver Resection: Novel Concerns.
    J Hepatol. 2018 Feb 20. pii: S0168-8278(18)30122.
    PubMed     Text format    


  107. LYU N, Kong Y, Mu L, Lin Y, et al
    Hepatic Arterial Infusion of Oxaliplatin plus Fluorouracil/Leucovorin versus Sorafenib for Advanced Hepatocellular Carcinoma.
    J Hepatol. 2018 Feb 19. pii: S0168-8278(18)30125.
    PubMed     Text format     Abstract available


  108. LI J, Lei Z, Wang K, Shen F, et al
    Reply to "Antiviral therapy improves survival in patients with HBV infection and intrahepatic cholangiocarcinoma undergoing liver resection: novel concerns".
    J Hepatol. 2018 Feb 17. pii: S0168-8278(18)30127.
    PubMed     Text format    


  109. COENRAAD MJ, Porcher R, Bendtsen F
    Hepatic and cardiac hemodynamics and systemic inflammation in cirrhosis: it takes three to tango.
    J Hepatol. 2018 Feb 17. pii: S0168-8278(18)30124.
    PubMed     Text format     Abstract available


  110. NISHIZAWA N, Ito Y, Eshima K, Ohkubo H, et al
    Inhibition of microsomal prostaglandin E synthase-1 facilitates liver repair after hepatic injury in mice.
    J Hepatol. 2018 Feb 16. pii: S0168-8278(18)30126.
    PubMed     Text format     Abstract available


  111. DUAN F, Wu H, Jia D, Wu W, et al
    O-GlcNAcylation of RACK1 promotes hepatocellular carcinogenesis.
    J Hepatol. 2018 Feb 14. pii: S0168-8278(18)30119.
    PubMed     Text format     Abstract available


  112. ZHANG P, Ge Z, Wang H, Feng W, et al
    Prolactin improves hepatic steatosis via CD36 pathway.
    J Hepatol. 2018 Feb 13. pii: S0168-8278(18)30115.
    PubMed     Text format     Abstract available


  113. YOON YI, Song GW, Lee SG, Hwang S, et al
    Outcome of ABO-incompatible adult living-donor liver transplantation for patients with hepatocellular carcinoma.
    J Hepatol. 2018 Feb 13. pii: S0168-8278(18)30113.
    PubMed     Text format     Abstract available


  114. GUIU B, Jouve JL, Schmitt A, Minello A, et al
    Intra-arterial Idarubicin_lipiodol without embolization in hepatocellular carcinoma: the LIDA-B phase I trial.
    J Hepatol. 2018 Feb 7. pii: S0168-8278(18)30069.
    PubMed     Text format     Abstract available


  115. KIM AY, Sinn DH, Jeong WK, Kim YK, et al
    Hepatobiliary MRI as novel selection criteria in liver transplantation for hepatocellular carcinoma.
    J Hepatol. 2018 Feb 2. pii: S0168-8278(18)30071.
    PubMed     Text format     Abstract available


  116. MOHKAM K, Dumont PN, Manichon AF, Jouvet JC, et al
    No touch multibipolar radiofrequency ablation vs. surgical resection for solitary hepatocellular carcinoma ranging from 2 to 5 cm.
    J Hepatol. 2018 Feb 1. pii: S0168-8278(18)30057.
    PubMed     Text format     Abstract available


  117. LIM C, Salloum C, Azoulay D
    Reply to Letter: "Liver resection for BCLC 0-A stage hepatocellular carcinoma: does the time to surgery not impact the prognosis".
    J Hepatol. 2018 Feb 1. pii: S0168-8278(18)30067.
    PubMed     Text format    


    January 2018
  118. PEI Y, Chen X, Zhang W
    Liver resection for BCLC 0-A stage hepatocellular carcinoma: does the time to surgery not impact the prognosis?
    J Hepatol. 2018 Jan 31. pii: S0168-8278(18)30065.
    PubMed     Text format    


  119. BUREAU C, Adebayo D, de Rieu MC, Elkrief L, et al
    Corrigendum to "Alfapump(R) system vs. large volume paracentesis for refractory ascites: A multicenter randomized controlled study" [J Hepatol 67 (2017) 940-949].
    J Hepatol. 2018 Jan 29. pii: S0168-8278(17)32532.
    PubMed     Text format    


  120. YU J, Xu QG, Wang ZG, Yang Y, et al
    Circular RNA cSMARCA5 inhibits growth and metastasis in hepatocellular carcinoma.
    J Hepatol. 2018 Jan 26. pii: S0168-8278(18)30055.
    PubMed     Text format     Abstract available


  121. GEHRKE N, Hovelmeyer N, Waisman A, Straub BK, et al
    Hepatocyte-specific deletion of IL1-RI attenuatesliver injury by blocking IL-1 driven autoinflammation.
    J Hepatol. 2018 Jan 20. pii: S0168-8278(18)30020.
    PubMed     Text format     Abstract available


  122. KARAMPATOU A, Han X, Kondili LA, Taliani G, et al
    Corrigendum to "Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV" [J Hepatol 68 (2018) 33-41].
    J Hepatol. 2018 Jan 20. pii: S0168-8278(18)30013.
    PubMed     Text format    


  123. THIELE M, Rausch V, Fluhr G, Kjaergaard M, et al
    Controlled Attenuation Parameter And Alcoholic Hepatic Steatosis: Diagnostic Accuracy and Role Of Alcohol Detoxification.
    J Hepatol. 2018 Jan 14. pii: S0168-8278(18)30016.
    PubMed     Text format     Abstract available


  124. SPREAFICO C, Sposito C, Vaiani M, Cascella T, et al
    Development of a prognostic score to predict response to yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasion.
    J Hepatol. 2018 Jan 10. pii: S0168-8278(18)30010.
    PubMed     Text format     Abstract available


  125. ORCI LA, Lacotte S, Delaune V, Slits F, et al
    Effects of the gut-liver axis on ischemia-mediated hepatocellular carcinoma recurrence in the mouse liver.
    J Hepatol. 2018 Jan 10. pii: S0168-8278(18)30009.
    PubMed     Text format     Abstract available


  126. LEVADA K, Guldiken N, Zhang X, Vella G, et al
    Hsp72 protects from liver injury via attenuation of hepatocellular death, oxidative stress and JNK-signaling.
    J Hepatol. 2018 Jan 10. pii: S0168-8278(18)30008.
    PubMed     Text format     Abstract available


  127. TURCO L, Garcia-Tsao G, Magnani I, Bianchini M, et al
    Cardiopulmonary hemodynamics and c-reactive protein as prognostic indicators in compensated and decompensated cirrhosis.
    J Hepatol. 2018 Jan 10. pii: S0168-8278(18)30011.
    PubMed     Text format     Abstract available


  128. THOMAS JA, Ramachandran P, Forbes SJ
    Studies of macrophage therapy for cirrhosis - from mice to men.
    J Hepatol. 2018 Jan 6. pii: S0168-8278(18)30002.
    PubMed     Text format    


    December 2017
  129. UTOH R, Komori J, Kuge H, Tatsumi K, et al
    Adult hepatocytes direct liver organogenesis through non-parenchymal cell recruitment in the kidney.
    J Hepatol. 2017 Dec 26. pii: S0168-8278(17)32531.
    PubMed     Text format     Abstract available


  130. XU B, Jiang M, Chu Y, Wang W, et al
    Gasdermin D plays a key role as a pyroptosis executor of non-alcoholic steatohepatitis in humans and mice.
    J Hepatol. 2017 Dec 19. pii: S0168-8278(17)32494.
    PubMed     Text format     Abstract available


  131. LI L, Barry V, Daffis S, Niu C, et al
    Anti-HBV Response to Toll-Like Receptor 7 Agonist GS-9620 is Associated with Intrahepatic Aggregates of T Cells and B Cells.
    J Hepatol. 2017 Dec 14. pii: S0168-8278(17)32490.
    PubMed     Text format     Abstract available


  132. CALDWELL S, Marchesini G
    Cryptogenic vs NASH-cirrhosis: The rose exists well before its name.
    J Hepatol. 2017 Dec 13. pii: S0168-8278(17)32488.
    PubMed     Text format    


  133. OVREHUS ALH, Krarup H, Birkemose I, Holm DK, et al
    Four weeks of ledipasvir/sofosbuvir and ribavirin with or without pegylated interferon for chronic hepatitis C in non-cirrhotic people who inject drugs. A randomized trial.
    J Hepatol. 2017 Dec 6. pii: S0168-8278(17)32475.
    PubMed     Text format    


  134. RATZIU V
    A critical review of endpoints for non-cirrhotic NASH therapeutic trials.
    J Hepatol. 2017 Dec 6. pii: S0168-8278(17)32481.
    PubMed     Text format     Abstract available


  135. VAN VUGT JLA, Alferink LJM, Buettner S, Gaspersz MP, et al
    A Model including Sarcopenia Surpasses the MELD Score in Predicting Waiting List Mortality in Cirrhotic Liver Transplant Candidates.
    J Hepatol. 2017 Dec 5. pii: S0168-8278(17)32474.
    PubMed     Text format     Abstract available


    November 2017
  136. LAU HH, Ng NHJ, Loo LSW, Jasmen J, et al
    The molecular functions of hepatocyte nuclear factors in and beyond the liver.
    J Hepatol. 2017 Nov 23. pii: S0168-8278(17)32451.
    PubMed     Text format     Abstract available


  137. LEE YH, Kim KJ, Yoo ME, Kim G, et al
    Association of nonalcoholic steatohepatitis with subclinical myocardial dysfunction in non-cirrhotic patients.
    J Hepatol. 2017 Nov 23. pii: S0168-8278(17)32448.
    PubMed     Text format     Abstract available


  138. NOBILI V, Mosca A, Scorletti E, Byrne CD, et al
    Reply 'Energy drinks and risk of non alcoholic steatohepatitis'.
    J Hepatol. 2017 Nov 23. pii: S0168-8278(17)32446.
    PubMed     Text format    


  139. ROBIN S, Buchanan R, Poole R
    Energy drinks and adolescents - a hepatic health hazard?
    J Hepatol. 2017 Nov 22. pii: S0168-8278(17)32444.
    PubMed     Text format    


  140. THULUVATH PJ, Kantsevoy S, Thuluvath AJ, Savva Y, et al
    Is Cryptogenic Cirrhosis Different from NASH Cirrhosis?
    J Hepatol. 2017 Nov 18. pii: S0168-8278(17)32441.
    PubMed     Text format     Abstract available


  141. LEI Z, Xia Y, Si A, Wang K, et al
    Antiviral Therapy Improves Survival in patients with HBV infection and Intrahepatic Cholangiocarcinoma undergoing Liver Resection.
    J Hepatol. 2017 Nov 16. pii: S0168-8278(17)32438.
    PubMed     Text format     Abstract available


  142. INNES H, Barclay ST, Hayes PC, Fraser A, et al
    The risk of hepatocellular carcinoma in cirrhotic patients with hepatitis C and sustained viral response: role of the treatment regimen.
    J Hepatol. 2017 Nov 15. pii: S0168-8278(17)32429.
    PubMed     Text format     Abstract available


  143. TERZI E, Iavarone M, Pompili M, Veronese L, et al
    Contrast enhanced ultrasound identifies hepatocellular carcinoma in cirrhosis: a large multicenter retrospective study.
    J Hepatol. 2017 Nov 10. pii: S0168-8278(17)32428.
    PubMed     Text format     Abstract available


  144. HU C, Li W, Tian F, Jiang K, et al
    Arid1a regulates response to anti-angiogenic therapy in advanced hepatocellular carcinoma.
    J Hepatol. 2017 Nov 4. pii: S0168-8278(17)32409.
    PubMed     Text format     Abstract available


  145. HAYES P, Mookerjee RP
    Early TIPS for portal hypertensive related bleeding: Is resource or education the reason for failure to show clear survival benefit?
    J Hepatol. 2017 Nov 2. pii: S0168-8278(17)32410.
    PubMed     Text format    


    October 2017
  146. MOHAMMED MS, Ferrier G, Abouda G, Corless L, et al
    Socio-economic deprivation significantly impacts clinical management and survival in hepatocellular carcinoma.
    J Hepatol. 2017 Oct 31. pii: S0168-8278(17)32403.
    PubMed     Text format    


  147. ASHHAB AA, Rodin H, Debes JD
    Hepatocellular carcinoma diagnosis and surveillance: Socioeconomic factors don't seem to matter, unless you are an immigrant-Authors-reply.
    J Hepatol. 2017 Oct 31. pii: S0168-8278(17)32404.
    PubMed     Text format    


  148. D'AMICO G, Morabito A, D'Amico M, Pasta L, et al
    Clinical states of cirrhosis and competing risks.
    J Hepatol. 2017 Oct 27. pii: S0168-8278(17)32399.
    PubMed     Text format     Abstract available


  149. ALAVI M, Janjua NZ, Chong M, Grebely J, et al
    The contribution of alcohol-use disorder to decompensated cirrhosis among people with hepatitis C: an international study.
    J Hepatol. 2017 Oct 26. pii: S0168-8278(17)32398.
    PubMed     Text format     Abstract available


  150. KIM G, Jang SY, Nam CM, Kang ES, et al
    Statin use and the risk of hepatocellular carcinoma in patients at high risk: a nationwide nested case-control study.
    J Hepatol. 2017 Oct 26. pii: S0168-8278(17)32397.
    PubMed     Text format     Abstract available


  151. KIM KM, Han CY, Kim JY, Cho SS, et al
    Galpha12 overexpression induced by miR16 dysregulation contributes to liver fibrosis by promoting autophagy in hepatic stellate cells.
    J Hepatol. 2017 Oct 25. pii: S0168-8278(17)32388.
    PubMed     Text format     Abstract available


  152. JACKSON R, Psarelli EE, Berhane S, Johnson PJ, et al
    Predictors of Sorafenib Benefit in Patients with Hepatocellular Carcinoma.
    J Hepatol. 2017 Oct 24. pii: S0168-8278(17)32389.
    PubMed     Text format    


  153. BRUIX J, Cheng AL, Llovet J
    Predictors of Sorafenib Benefit in Patients with Hepatocellular Carcinoma.
    J Hepatol. 2017 Oct 24. pii: S0168-8278(17)32392.
    PubMed     Text format    


  154. NAULT JC, Sutter O, Nahon P, Ganne-Carrie N, et al
    Percutaneous treatment of hepatocellular carcinoma: state of the art and innovations.
    J Hepatol. 2017 Oct 12. pii: S0168-8278(17)32351.
    PubMed     Text format     Abstract available


  155. YU Y, Wang J, Li G, Shen C, et al
    Nucleos(t)ide analogue interruption: Alternative approach to intrahepatic set point for spontaneous control of HBV replication?
    J Hepatol. 2017 Oct 6. pii: S0168-8278(17)32346.
    PubMed     Text format    


  156. FUJIWARA N, Friedman SL, Goossens N, Hoshida Y, et al
    Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine.
    J Hepatol. 2017 Oct 5. pii: S0168-8278(17)32328.
    PubMed     Text format     Abstract available


  157. LIM C, Bhangui P, Salloum C, Gavara CG, et al
    Impact of time to surgery in the outcome of patients with liver resection for BCLC 0-A stage hepatocellular carcinoma.
    J Hepatol. 2017 Oct 5. pii: S0168-8278(17)32331.
    PubMed     Text format     Abstract available


    September 2017
  158. VERHOEVEN CJ, Selten JW, Roest HP, Farid WRR, et al
    Corrigendum to "MicroRNA profiles in graft preservation solution are predictive of ischemic-type biliary lesions after liver transplantation" [J Hepatol 2013; 59:1231-1238].
    J Hepatol. 2017 Sep 27. pii: S0168-8278(17)32279.
    PubMed     Text format    


  159. GANDHI CR
    Hepatic stellate cell activation and pro-fibrogenic signals.
    J Hepatol. 2017 Sep 19. pii: S0168-8278(17)32068.
    PubMed     Text format    


  160. BESTE LA, Green PK, Berry K, Kogut MJ, et al
    Reply to Letters to the Editor from Mazzarelli et al. entitled "Direct-acting antiviral therapy in patients with hepatocellular cancer: the timing of treatment is everything" and Tammineedi et al. entitled "More extended indication of DAA therapy in p
    J Hepatol. 2017 Sep 19. pii: S0168-8278(17)32292.
    PubMed     Text format    


  161. THABUT D, Pauwels A, Carbonell N, Remy AJ, et al
    Cirrhotic patients with portal hypertension-related bleeding and an indication for early-TIPS: a large multicentre audit with real-life results.
    J Hepatol. 2017 Sep 13. pii: S0168-8278(17)32281.
    PubMed     Text format     Abstract available


  162. PRENNER S, Kulik L
    Reply to "Treatment failure after interferon-free treatment of hepatitis C as a clue of a yet undetected hepatocellular carcinoma".
    J Hepatol. 2017 Sep 13. pii: S0168-8278(17)32283.
    PubMed     Text format    


  163. HUANG A, Zhao X, Yang XR, Li FQ, et al
    Corrigendum to "Circumventing intratumoral heterogeneity to identify potential therapeutic targets in hepatocellular carcinoma" [J Hepatol 67 (2017) 293-301].
    J Hepatol. 2017 Sep 12. pii: S0168-8278(17)32207.
    PubMed     Text format    


  164. MOOKERJEE RP, Mehta G, Balasubramaniyan V, Mohamed FEZ, et al
    Corrigendum to "Hepatic dimethylarginine-dimethylaminohydrolase1 is reduced in cirrhosis and is a target for therapy in portal hypertension" [J Hepatol 62 (2015) 325-331].
    J Hepatol. 2017 Sep 8. pii: S0168-8278(17)32209.
    PubMed     Text format    


  165. FANGAZIO S, Camatta D, Minh MT, Ceriani E, et al
    Treatment failure after interferon-free treatment of hepatitis C as a clue of a yet undetected hepatocellular carcinoma.
    J Hepatol. 2017 Sep 7. pii: S0168-8278(17)32280.
    PubMed     Text format    


  166. IOANNOU GN, Green PK, Berry K
    HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma.
    J Hepatol. 2017 Sep 5. pii: S0168-8278(17)32273.
    PubMed     Text format     Abstract available


  167. WANG X, Mao W, Fang C, Tian S, et al
    Dusp14 protects against hepatic ischemia-reperfusion injury via Tak1 suppression.
    J Hepatol. 2017 Sep 5. pii: S0168-8278(17)32275.
    PubMed     Text format     Abstract available


  168. QI X, Liu F, Li Z, Chen S, et al
    Insufficient accuracy of computed tomography-based portal pressure assessment in hepatitis B virus-related cirrhosis.
    J Hepatol. 2017 Sep 5. pii: S0168-8278(17)32277.
    PubMed     Text format    


  169. IRANMANESH P, Toso C
    Reply to the Letter to the Editor by Qi et al. entitled "Insufficient accuracy of computed tomography-based portal pressure assessment in hepatitis B virus-related cirrhosis".
    J Hepatol. 2017 Sep 5. pii: S0168-8278(17)32274.
    PubMed     Text format    


  170. URBAN SK, Krawczyk M, Willms A, Sanger H, et al
    Diagnostic and Prognostic Role of Circulating Microparticles in Hepatocellular Carcinoma.
    J Hepatol. 2017 Sep 1. pii: S0168-8278(17)32262.
    PubMed     Text format    


  171. MAZZARELLI C, Cannon MD, Belli LS, Agarwal K, et al
    Direct-acting antiviral therapy in patients with hepatocellular cancer: the timing of treatment is everything.
    J Hepatol. 2017 Sep 1. pii: S0168-8278(17)32265.
    PubMed     Text format    


  172. HUANG R, Liu Y, Wang J, Xia J, et al
    Risk factors of hepatocellular carcinoma after hepatitis B surface antigen seroclearance.
    J Hepatol. 2017 Sep 1. pii: S0168-8278(17)32270.
    PubMed     Text format    


  173. WANG J, Yu Y, Li G, Shen C, et al
    Relationship between serum HBV RNA levels and intrahepatic viral as well as histologic activity markers in entecavir-treated patients.
    J Hepatol. 2017 Sep 1. pii: S0168-8278(17)32261.
    PubMed     Text format     Abstract available


  174. WANG M, Shen G, Xu L, Liu X, et al
    IL-1 receptor like 1 protects against alcoholic liver injury by limiting NF-kappaB activation in hepatic macrophages.
    J Hepatol. 2017 Sep 1. pii: S0168-8278(17)32263.
    PubMed     Text format     Abstract available


  175. YIP TC, Chan HL, Wong VW, Wong GL, et al
    Reply to: "Risk factors of hepatocellular carcinoma after hepatitis B surface antigen seroclearance".
    J Hepatol. 2017 Sep 1. pii: S0168-8278(17)32266.
    PubMed     Text format    


  176. PONZIANI FR, Giarretta I, Nicoletti A, Gatto I, et al
    Diagnostic and Prognostic Role of Circulating Microparticles in Hepatocellular Carcinoma.
    J Hepatol. 2017 Sep 1. pii: S0168-8278(17)32257.
    PubMed     Text format    


  177. GROSSI G, Loglio A, Facchetti F, Borghi M, et al
    Tenofovir alafenamide as a Rescue Therapy in a Cirrhotic HBV Patient with a Hystory of Fanconi Syndrome and Multidrug Resistance: A Case Report.
    J Hepatol. 2017 Sep 1. pii: S0168-8278(17)32260.
    PubMed     Text format     Abstract available


    August 2017
  178. SHARMA SA, Kowgier M, Hansen BE, Pieter Brouwer W, et al
    Toronto HCC Risk Index: A validated scoring system to predict 10-year risk of HCC in patients with cirrhosis.
    J Hepatol. 2017 Aug 24. pii: S0168-8278(17)32248.
    PubMed     Text format     Abstract available


  179. TORRECILLA S, Sia D, Harrington AN, Zhang Z, et al
    Trunk events present minimal intra- and inter-tumoral heterogeneity in hepatocellular carcinoma.
    J Hepatol. 2017 Aug 23. pii: S0168-8278(17)32252.
    PubMed     Text format     Abstract available


  180. CHIANG DY, Villanueva A
    Progress towards molecular patient stratification of hepatocellular carcinoma: lost in translation?
    J Hepatol. 2017 Aug 21. pii: S0168-8278(17)32210.
    PubMed     Text format    


  181. PETTA S, Marchesini G
    Corrigendum to "Coffee and tea breaks for liver health" [J Hepatol 67 (2017) 221-223].
    J Hepatol. 2017 Aug 16. pii: S0168-8278(17)32186.
    PubMed     Text format    


  182. REBOUISSOU S, Zucman-Rossi J, Moreau R, Qiu Z, et al
    Note of caution: contaminations of hepatocellular cell lines.
    J Hepatol. 2017 Aug 11. pii: S0168-8278(17)32206.
    PubMed     Text format    


  183. DONATO MF, Invernizzi F, Rossi G, Iavarone M, et al
    Interferon-free therapy of hepatitis C during wait list and post-transplant risk of hepatocellular carcinoma recurrence.
    J Hepatol. 2017 Aug 10. pii: S0168-8278(17)32200.
    PubMed     Text format    


  184. MAJUMDAR A, Bailey M, Kemp WM, Bellomo R, et al
    Declining mortality in critically ill patients with cirrhosis in Australia and New Zealand between 2000 and 2015.
    J Hepatol. 2017 Aug 9. pii: S0168-8278(17)32198.
    PubMed     Text format     Abstract available


  185. WAZIRY R, Hajarizadeh B, Grebely J, Amin J, et al
    Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression.
    J Hepatol. 2017 Aug 9. pii: S0168-8278(17)32199.
    PubMed     Text format     Abstract available


  186. DONG YANG J, Leise MD
    Reply to " Interferon-free therapy of hepatitis C during wait list and post transplant risk of hepatocellular carcinoma recurrence".
    J Hepatol. 2017 Aug 8. pii: S0168-8278(17)32201.
    PubMed     Text format    


  187. SEBASTIAN M, Johannes M
    Is Room Temperature Susceptometry really an accurate method to assess hepatocellular iron? A response.
    J Hepatol. 2017 Aug 7. pii: S0168-8278(17)32192.
    PubMed     Text format    


  188. PAISANT A, Laine F, Gandon Y, Bardou-Jacquet E, et al
    Is Room Temperature Susceptometer really an accurate method to assess hepatocellular iron?
    J Hepatol. 2017 Aug 5. pii: S0168-8278(17)32193.
    PubMed     Text format    


  189. THALHEIMER U, Giannelli V, Maimone S
    Non selective beta blockers in cirrhosis.
    J Hepatol. 2017 Aug 5. pii: S0168-8278(17)32194.
    PubMed     Text format    


  190. DEZSO K, Rokusz A, Bugyik E, Szucs A, et al
    Erratum to "Human liver regeneration in advanced cirrhosis is organized by the portal tree" [J Hepatol 66 (2017) 778-786].
    J Hepatol. 2017;67:430-436.
    PubMed     Text format    


    July 2017
  191. LEE S, Kim SH
    Reply to: "How to Better Predict Microvascular Invasion and Recurrence of Hepatocellular Carcinoma".
    J Hepatol. 2017 Jul 21. pii: S0168-8278(17)32156.
    PubMed     Text format    


  192. XU XF, Yu JJ, Xing H, Shen F, et al
    How to Better Predict Microvascular Invasion and Recurrence of Hepatocellular Carcinoma.
    J Hepatol. 2017 Jul 20. pii: S0168-8278(17)32157.
    PubMed     Text format    


  193. BERG T, Simon KG, Mauss S, Schott E, et al
    Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients - FINITE study.
    J Hepatol. 2017 Jul 20. pii: S0168-8278(17)32155.
    PubMed     Text format     Abstract available


  194. LEE WM
    Public Health: Acetaminophen (APAP) Hepatotoxicity- Isn't It Time for APAP to Go Away?
    J Hepatol. 2017 Jul 19. pii: S0168-8278(17)32148.
    PubMed     Text format     Abstract available


  195. NAULT JC, Paradis V, Cherqui D, Vilgrain V, et al
    Molecular classification of hepatocellular adenoma in clinical practice.
    J Hepatol. 2017 Jul 18. pii: S0168-8278(17)32152.
    PubMed     Text format     Abstract available


  196. PIANO S, Tonon M, Vettore E, Stanco M, et al
    Incidence, predictors and outcomes of acute-on-chronic liver failure in outpatients with cirrhosis.
    J Hepatol. 2017 Jul 18. pii: S0168-8278(17)32151.
    PubMed     Text format     Abstract available


  197. ZHANG S, Song X, Cao D, Xu Z, et al
    Pan-mTOR inhibitor MLN0128 is effective against intrahepatic cholangiocarcinoma induced in mice by AKT and Yap co-expression.
    J Hepatol. 2017 Jul 18. pii: S0168-8278(17)32149.
    PubMed     Text format     Abstract available


  198. KOLLY P, Waidmann O, Vermehren J, Moreno C, et al
    Hepatocellular Carcinoma Recurrence after Direct Antiviral Agent Treatment: a European Multicentre Study.
    J Hepatol. 2017 Jul 18. pii: S0168-8278(17)32150.
    PubMed     Text format    


  199. ROBERTO C, Valeria R, Cristina N, Simona B, et al
    Gut-derived endotoxin stimulates factor viii secretion from endothelial cells. implications for hypercoagulability in cirrhosis.
    J Hepatol. 2017 Jul 14. pii: S0168-8278(17)32145.
    PubMed     Text format     Abstract available


  200. FICKERT P, Wagner M
    Biliary bile acids in hepatobiliary injury - What is the link?
    J Hepatol. 2017 Jul 13. pii: S0168-8278(17)32008.
    PubMed     Text format     Abstract available


  201. GAVRIILIDIS P, Roberts KJ, Askari A, Sutcliffe RP, et al
    Evaluation of the Current Guidelines for Resection of hepatocellular carcinoma Using the Appraisal of Guidelines Research and Evaluation II Instrument.
    J Hepatol. 2017 Jul 6. pii: S0168-8278(17)32136.
    PubMed     Text format     Abstract available


  202. STENGEL S, Stallmach A, Richter K, Landrock A, et al
    Serum metabolic signatures in patients with overt hepatic encephalopathy.
    J Hepatol. 2017 Jul 6. pii: S0168-8278(17)32138.
    PubMed     Text format    


  203. WEISS N, Colsch B, Fenaille F, Junot C, et al
    Metabolic signature for severe cirrhosis with inflammation or hepatic encephalopathy: do we really face two different entities?
    J Hepatol. 2017 Jul 5. pii: S0168-8278(17)32140.
    PubMed     Text format    


  204. BRUIX J, Cheng AL, Meinhardt G, Nakajima K, et al
    Prognostic Factors and Predictors of Sorafenib Benefit in Patients With Hepatocellular Carcinoma: Analysis of Two Phase 3 Studies.
    J Hepatol. 2017 Jul 4. pii: S0168-8278(17)32134.
    PubMed     Text format     Abstract available


  205. SAMJI H, Yu A, Kuo M, Alavi M, et al
    Late hepatitis B and C diagnosis in relation to disease decompensation and hepatocellular carcinoma development.
    J Hepatol. 2017 Jul 3. pii: S0168-8278(17)32133.
    PubMed     Text format     Abstract available


    June 2017
  206. BECK M, Schirmacher P, Singer S
    Alterations of the nuclear transport system in hepatocellular carcinoma - new basis for therapeutic strategies.
    J Hepatol. 2017 Jun 30. pii: S0168-8278(17)32122.
    PubMed     Text format     Abstract available


  207. YIP TC, Chan HL, Wong VW, Tse YK, et al
    Impact of age and gender on risk of hepatocellular carcinoma after hepatitis B surface antigen seroclearance.
    J Hepatol. 2017 Jun 23. pii: S0168-8278(17)32092.
    PubMed     Text format     Abstract available


  208. MARIN V, Poulsen K, Odena G, McMullen MR, et al
    Hepatocyte-derived macrophage migration inhibitory factor mediates alcohol-induced liver injury in mice and patients.
    J Hepatol. 2017 Jun 21. pii: S0168-8278(17)32086.
    PubMed     Text format     Abstract available


  209. XIANG X, You XM, Zhong JH, Li LQ, et al
    Hepatocellular carcinoma in the absence of cirrhosis in patients with chronic hepatitis B virus infection.
    J Hepatol. 2017 Jun 21. pii: S0168-8278(17)32081.
    PubMed     Text format    


  210. POORDAD F, Nelson DR, Feld JJ, Fried MW, et al
    Safety of the 2D/3D direct acting antiviral regimen in HCV-induced Child-Pugh A cirrhosis - a pooled analysis.
    J Hepatol. 2017 Jun 20. pii: S0168-8278(17)32083.
    PubMed     Text format     Abstract available


  211. ARTRU F, Louvet A, Ruiz I, Levesque E, et al
    Liver transplantation in the most severely ill cirrhotic patients: a multicenter study in acute-on-chronic liver failure grade 3.
    J Hepatol. 2017 Jun 20. pii: S0168-8278(17)32079.
    PubMed     Text format     Abstract available


  212. BERTUCCIO P, Turati F, Carioli G, Rodriguez T, et al
    RE: Global Trends and Predictions in Hepatocellular Carcinoma Mortality.
    J Hepatol. 2017 Jun 18. pii: S0168-8278(17)32084.
    PubMed     Text format    


  213. CHAYANUPATKUL M, Kanwal F
    Author's reply to "Inappropriate use of FIB-4 index for cirrhosis detection in hepatocellular carcinoma patients".
    J Hepatol. 2017 Jun 18. pii: S0168-8278(17)32074.
    PubMed     Text format    


  214. CHAYANUPATKUL M, Kanwal F
    Author's reply to "Hepatocellular carcinoma (HCC) in the absence of cirrhosis in patients with chronic hepatitis B virus infection".
    J Hepatol. 2017 Jun 18. pii: S0168-8278(17)32075.
    PubMed     Text format    


  215. PANG Q, Liu HC, Zhou L, Jin H, et al
    Inappropriateuse of FIB-4 index for cirrhosis detection in hepatocellular carcinoma patients.
    J Hepatol. 2017 Jun 18. pii: S0168-8278(17)32082.
    PubMed     Text format    


  216. NAGATA H, Nakagawa M, Asahina Y, Sato A, et al
    Effect of interferon-based and -free therapy on early occurrence and recurrence of hepatocellular carcinoma in chronic hepatitis C.
    J Hepatol. 2017 Jun 13. pii: S0168-8278(17)32070.
    PubMed     Text format     Abstract available


  217. KALAMBOKIS GN, Baltayannis G, Christodoulou D, Christou L, et al
    Beta adrenergic blockade and advanced cirrhosis: does it really improve survival in patients with acute-on-chronic liver failure?
    J Hepatol. 2017 Jun 6. pii: S0168-8278(17)32064.
    PubMed     Text format    


    May 2017
  218. TERATANI T, Tomita K, Suzuki T, Furuhashi H, et al
    Free cholesterol accumulation in liver sinusoidal endothelial cells exacerbates acetaminophen hepatotoxicity via TLR9 signaling.
    J Hepatol. 2017 May 26. pii: S0168-8278(17)32056.
    PubMed     Text format     Abstract available


  219. LU Z, Zuo B, Jing R, Gao X, et al
    Dendritic cell-derived exosomes elicit tumor regression in autochthonous hepatocellular carcinoma mouse models.
    J Hepatol. 2017 May 23. pii: S0168-8278(17)32055.
    PubMed     Text format     Abstract available


  220. CALDERARO J, Couchy G, Imbeaud S, Amaddeo G, et al
    Histological Subtypes of Hepatocellular Carcinoma Are Related To Gene Mutations and Molecular Tumour Classification.
    J Hepatol. 2017 May 19. pii: S0168-8278(17)32050.
    PubMed     Text format     Abstract available


  221. PEMBROKE T, Deschenes M, Lebouche B, Benmassaoud A, et al
    Hepatic steatosis progresses faster in HIV mono-infected than HIV/HCV co-infected patients and is associated with liver fibrosis.
    J Hepatol. 2017 May 17. pii: S0168-8278(17)32047.
    PubMed     Text format     Abstract available


  222. DE GALARRETA MR, Lujambio A
    Therapeutic editing of hepatocyte genome in vivo.
    J Hepatol. 2017 May 17. pii: S0168-8278(17)32048.
    PubMed     Text format     Abstract available


  223. ANDREASSON K, Waldenstrom J, Westin J, Norrgren H, et al
    JHEPAT-D-17-00297 R1: Cartilage oligomeric matrix protein associates with hepatic inflammation and fibrosis in hepatitis C virus infection.
    J Hepatol. 2017 May 17. pii: S0168-8278(17)32044.
    PubMed     Text format    


  224. WANG Q, Lv Y, Bai M, Wang Z, et al
    Eight millimeter covered TIPS does not compromise shunt function but reduces hepatic encephalopathy in preventing variceal rebleeding.
    J Hepatol. 2017 May 12. pii: S0168-8278(17)32015.
    PubMed     Text format     Abstract available


  225. ASHHAB AA, Rodin H, Powell J, Debes JD, et al
    Hepatocellular carcinoma diagnosis and surveillance: Socioeconomic factors don't seem to matter, unless you are an immigrant.
    J Hepatol. 2017 May 10. pii: S0168-8278(17)32012.
    PubMed     Text format    


  226. SHIN WJ, Hwang GS
    Reply to: "Pressure volume curves in cirrhosis: more than meets the eye".
    J Hepatol. 2017 May 9. pii: S0168-8278(17)32010.
    PubMed     Text format    


  227. RIPOLL C, Yotti R, Banares R, Bermejo J, et al
    Pressure Volume Curves in Cirrhosis: more than meets the eye.
    J Hepatol. 2017 May 8. pii: S0168-8278(17)32006.
    PubMed     Text format    


  228. TAN-GARCIA A, Wai LE, Zheng D, Ceccarello E, et al
    Intrahepatic CD206+ macrophages contribute to inflammation in advanced viral-related liver disease.
    J Hepatol. 2017 May 5. pii: S0168-8278(17)32004.
    PubMed     Text format     Abstract available


  229. LEE S, Kim SH, Lee JE, Sinn DH, et al
    Preoperative Gadoxetic acid-enhanced MRI for Predicting Microvascular Invasion in Patients with Single hepatocellular carcinoma.
    J Hepatol. 2017 May 5. pii: S0168-8278(17)32005.
    PubMed     Text format     Abstract available


  230. MUELLER J, Raisi H, Rausch V, Peccerella T, et al
    Sensitive and non-invasive assessment of hepatocellular iron using a novel room-temperature susceptometer.
    J Hepatol. 2017 May 5. pii: S0168-8278(17)32000.
    PubMed     Text format     Abstract available


  231. NADIM MK, DiNorcia J, Ji L, Groshen S, et al
    Inequity In Organ Allocation For Patients Awaiting Liver Transplantation: Rationale for Uncapping the Model for End-Stage Liver Disease.
    J Hepatol. 2017 May 5. pii: S0168-8278(17)32003.
    PubMed     Text format     Abstract available


  232. VAUTHEY JN, Mizuno T, Overman MJ, Soubrane O, et al
    Can we navigate chemotherapy-induced hepatic injuries from pathology to bedside?
    J Hepatol. 2017 May 2. pii: S0168-8278(17)30252.
    PubMed     Text format    


  233. MOSCA A, Nobili V, De Vito R, Crudele A, et al
    Serum uric acid concentrations and fructose consumption are independently associated with NASH in children and adolescents.
    J Hepatol. 2017;66:1031-1036.
    PubMed     Text format     Abstract available


  234. SANDBOTHE M, Buurman R, Reich N, Greiwe L, et al
    The microRNA-449 family inhibits TGF-beta-mediated liver cancer cell migration by targeting SOX4.
    J Hepatol. 2017;66:1012-1021.
    PubMed     Text format     Abstract available


  235. KARLAS T, Petroff D, Sasso M, Fan JG, et al
    Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis.
    J Hepatol. 2017;66:1022-1030.
    PubMed     Text format     Abstract available


  236. HUANG K, Du M, Tan X, Yang L, et al
    PARP1-mediated PPARalpha poly(ADP-ribosyl)ation suppresses fatty acid oxidation in non-alcoholic fatty liver disease.
    J Hepatol. 2017;66:962-977.
    PubMed     Text format     Abstract available


    April 2017
  237. KLINGENBERG M, Matsuda A, Diederichs S, Patel T, et al
    Non-coding RNA in hepatocellular carcinoma: Mechanisms, biomarkers and therapeutic targets.
    J Hepatol. 2017 Apr 21. pii: S0168-8278(17)30250.
    PubMed     Text format     Abstract available


  238. BRITO-AZEVEDO A
    Carvedilol and survival in cirrhosis with ascites: a cognitive bias?
    J Hepatol. 2017 Apr 20. pii: S0168-8278(17)30219.
    PubMed     Text format    


  239. BRUNO S, Maisonneuve P
    Response to the letter regarding the manuscript "Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population".
    J Hepatol. 2017 Apr 20. pii: S0168-8278(17)30216.
    PubMed     Text format    


  240. SEIDEL RA, Claudel T, Schleser FA, Ojha NK, et al
    Impact of higher-order heme degradation products on hepatic function and hemodynamics.
    J Hepatol. 2017 Apr 12. pii: S0168-8278(17)30208.
    PubMed     Text format     Abstract available


  241. KWO PY, Poordad F, Asatryan A, Wang S, et al
    Glecaprevir and Pibrentasvir Yield High response Rates in Patients with HCV Genotype 1-6 without Cirrhosis.
    J Hepatol. 2017 Apr 12. pii: S0168-8278(17)30211.
    PubMed     Text format     Abstract available


  242. HASSON H, Merli M, Messina E, Bhoori S, et al
    Occurrence of hepatocellular carcinoma in HIV/HCV co-infected patients treated with direct-acting antivirals.
    J Hepatol. 2017 Apr 11. pii: S0168-8278(17)30203.
    PubMed     Text format     Abstract available


  243. TAPPER EB, Sengupta N
    Testing for elevated liver enzymes: central to clinical Hepatology but in need of more data.
    J Hepatol. 2017 Apr 6. pii: S0168-8278(17)30199.
    PubMed     Text format    


  244. CARUSO S, Calderaro J, Letouze E, Nault JC, et al
    Germline and somatic DICER1 mutations in familial and sporadic liver tumors.
    J Hepatol. 2017;66:734-742.
    PubMed     Text format     Abstract available


  245. KOPEC AK, Joshi N, Cline-Fedewa H, Wojcicki AV, et al
    Fibrin(ogen) drives repair after acetaminophen-induced liver injury via leukocyte alphaMbeta2 integrin-dependent upregulation of Mmp12.
    J Hepatol. 2017;66:787-797.
    PubMed     Text format     Abstract available


  246. WOOLBRIGHT BL, Jaeschke H
    Role of the inflammasome in acetaminophen-induced liver injury and acute liver failure.
    J Hepatol. 2017;66:836-848.
    PubMed     Text format     Abstract available


  247. FERRERE G, Wrzosek L, Cailleux F, Turpin W, et al
    Fecal microbiota manipulation prevents dysbiosis and alcohol-induced liver injury in mice.
    J Hepatol. 2017;66:806-815.
    PubMed     Text format     Abstract available


    March 2017
  248. KIM JY, Park KJ, Hwang JY, Kim GH, et al
    Activating Transcription Factor 3 Is a Target Molecule Linking Hepatic Steatosis to Impaired Glucose Homeostasis.
    J Hepatol. 2017 Mar 29. pii: S0168-8278(17)30187.
    PubMed     Text format     Abstract available


  249. QURINO L, Massimo R, Jan L
    Proposal of a novel MELD exception point system for hepatocellular carcinoma: Dynamics better than tumor characteristics?
    J Hepatol. 2017 Mar 24. pii: S0168-8278(17)30180.
    PubMed     Text format    


  250. BHAT M, Ghali P, Bilodeau M
    Reply to: "Proposal of a novel MELD exception point system for hepatocellular carcinoma: Dynamics better than tumor characteristics?"
    J Hepatol. 2017 Mar 24. pii: S0168-8278(17)30183.
    PubMed     Text format    


  251. PREZIOSI ME, Singh S, Valore EV, Jung CL, et al
    Mice lacking liver-specific beta-catenin develop steatohepatitis and fibrosis after iron overload.
    J Hepatol. 2017 Mar 21. pii: S0168-8278(17)30146.
    PubMed     Text format     Abstract available


  252. BERTUCCIO P, Turati F, Carioli G, Rodriguez T, et al
    Global Trends and Predictions in Hepatocellular Carcinoma Mortality.
    J Hepatol. 2017 Mar 20. pii: S0168-8278(17)30145.
    PubMed     Text format     Abstract available


  253. URBAN TJ, Nicoletti P, Chalasani N, Serrano J, et al
    Minocycline Hepatotoxicity: Clinical characterization and identification of HLA-B * 35:02 as a risk factor.
    J Hepatol. 2017 Mar 17. pii: S0168-8278(17)30144.
    PubMed     Text format     Abstract available


  254. HUANG A, Zhao X, Yang XR, Li FQ, et al
    Circumventing intratumoral heterogeneity to identify potential therapeutic targets in hepatocellular carcinoma.
    J Hepatol. 2017 Mar 17. pii: S0168-8278(17)30139.
    PubMed     Text format     Abstract available


  255. VILARINHO S, Erson-Omay Z, Mitchell-Richards K, Cha C, et al
    Exome Analysis of the Evolutionary Path of Hepatocellular Adenoma-Carcinoma Transition, Vascular Invasion and Brain Dissemination.
    J Hepatol. 2017 Mar 17. pii: S0168-8278(17)30143.
    PubMed     Text format     Abstract available


  256. PATOURAUX S, Rousseau D, Bonnafous S, Lebeaupin C, et al
    CD44 is a key player in non-alcoholic steatohepatitis.
    J Hepatol. 2017 Mar 16. pii: S0168-8278(17)30137.
    PubMed     Text format     Abstract available


  257. JOSHI D, Gupta N, Samyn M, Deheragoda M, et al
    The management of childhood liver diseases in adulthood.
    J Hepatol. 2017;66:631-644.
    PubMed     Text format     Abstract available


  258. LACKNER C, Spindelboeck W, Haybaeck J, Douschan P, et al
    Histological parameters and alcohol abstinence determine long-term prognosis in patients with alcoholic liver disease.
    J Hepatol. 2017;66:610-618.
    PubMed     Text format     Abstract available


  259. RAMIREZ T, Li YM, Yin S, Xu MJ, et al
    Aging aggravates alcoholic liver injury and fibrosis in mice by downregulating sirtuin 1 expression.
    J Hepatol. 2017;66:601-609.
    PubMed     Text format     Abstract available


  260. LUKACS-KORNEK V, Lammert F
    The progenitor cell dilemma: Cellular and functional heterogeneity in assistance or escalation of liver injury.
    J Hepatol. 2017;66:619-630.
    PubMed     Text format     Abstract available


  261. SPIRLI C, Mariotti V, Villani A, Fabris L, et al
    Adenylyl cyclase 5 links changes in calcium homeostasis to cAMP-dependent cyst growth in polycystic liver disease.
    J Hepatol. 2017;66:571-580.
    PubMed     Text format     Abstract available


  262. LANGIEWICZ M, Schlegel A, Saponara E, Linecker M, et al
    Hedgehog pathway mediates early acceleration of liver regeneration induced by a novel two-staged hepatectomy in mice.
    J Hepatol. 2017;66:560-570.
    PubMed     Text format     Abstract available


    February 2017
  263. NAKAGAWA R, Muroyama R, Saeki C, Goto K, et al
    miR-425 regulates inflammatory cytokine production in CD4+ T cells via N-Ras upregulation in primary biliary cholangitis.
    J Hepatol. 2017 Feb 9. pii: S0168-8278(17)30066.
    PubMed     Text format     Abstract available


  264. TREBICKA J
    Emergency TIPS in a Child-Pugh B patient: When does the window of opportunity open and close?
    J Hepatol. 2017;66:442-450.
    PubMed     Text format     Abstract available


  265. MA J, Hwang SJ, Pedley A, Massaro JM, et al
    Bi-directional analysis between fatty liver and cardiovascular disease risk factors.
    J Hepatol. 2017;66:390-397.
    PubMed     Text format     Abstract available


  266. TAPPER EB, Saini SD, Sengupta N
    Extensive testing or focused testing of patients with elevated liver enzymes.
    J Hepatol. 2017;66:313-319.
    PubMed     Text format     Abstract available


    January 2017
  267. HASHIDA R, Kawaguchi T, Bekki M, Omoto M, et al
    Aerobic vs. resistance exercise in non-alcoholic fatty liver disease: A systematic review.
    J Hepatol. 2017;66:142-152.
    PubMed     Text format     Abstract available


  268. STICKEL F, Moreno C, Hampe J, Morgan MY, et al
    The genetics of alcohol dependence and alcohol-related liver disease.
    J Hepatol. 2017;66:195-211.
    PubMed     Text format     Abstract available


  269. GARIANI K, Ryu D, Menzies KJ, Yi HS, et al
    Inhibiting poly ADP-ribosylation increases fatty acid oxidation and protects against fatty liver disease.
    J Hepatol. 2017;66:132-141.
    PubMed     Text format     Abstract available


  270. GUIXE-MUNTET S, de Mesquita FC, Vila S, Hernandez-Gea V, et al
    Cross-talk between autophagy and KLF2 determines endothelial cell phenotype and microvascular function in acute liver injury.
    J Hepatol. 2017;66:86-94.
    PubMed     Text format     Abstract available


  271. POISSON J, Lemoinne S, Boulanger C, Durand F, et al
    Liver sinusoidal endothelial cells: Physiology and role in liver diseases.
    J Hepatol. 2017;66:212-227.
    PubMed     Text format     Abstract available


  272. HOCQUELET A, Aube C, Rode A, Cartier V, et al
    Comparison of no-touch multi-bipolar vs. monopolar radiofrequency ablation for small HCC.
    J Hepatol. 2017;66:67-74.
    PubMed     Text format     Abstract available


    December 2016
  273. CRUZ-LEMINI M, Altamirano J, Ndugga N, Abraldes JG, et al
    Reply to: Heavy daily alcohol intake at the population level predicts the weight of alcohol in cirrhosis burden worldwide: methodological issues of confounding and prediction models.
    J Hepatol. 2016 Dec 30. pii: S0168-8278(16)30756.
    PubMed     Text format    


  274. AYUBI E, Safiri S, Sani M, Khazaei S, et al
    Heavy daily alcohol intake at the population level predicts the weight of alcohol in cirrhosis burden worldwide: methodological issues of confounding and prediction models.
    J Hepatol. 2016 Dec 30. pii: S0168-8278(16)30758.
    PubMed     Text format    


    November 2016
  275. TSAI PC, Huang CF, Yu ML
    Unexpected early tumor recurrence in patients with hepatitis C virus -related hepatocellular carcinoma undergoing interferon-free therapy: issue of tie interval between HCC treatment and antiviral therapy.
    J Hepatol. 2016 Nov 10. pii: S0168-8278(16)30646.
    PubMed     Text format    


    October 2016
  276. WANNHOFF A, Friedrich K, Gotthardt DN
    Reduced influence of procoagulant changes on survival in patients with advanced cirrhosis.
    J Hepatol. 2016 Oct 24. pii: S0168-8278(16)30583.
    PubMed     Text format    


  277. POTZE W, Sanyal AJ, Lisman T
    How to assess hemostatic capacity in patients with cirrhosis?
    J Hepatol. 2016 Oct 18. pii: S0168-8278(16)30576.
    PubMed     Text format    


    September 2016
  278. FUCHS CD, Paumgartner G, Wahlstrom A, Schwabl P, et al
    Metabolic Preconditioning Protects BSEP/ABCB11-/- Mice against Cholestatic Liver Injury.
    J Hepatol. 2016 Sep 1. pii: S0168-8278(16)30482.
    PubMed     Text format     Abstract available


    July 2016
  279. PAIS R, Sidney Barritt A 4th, Calmus Y, Scatton O, et al
    Nafld and liver transplantation: current burden and expected challenges.
    J Hepatol. 2016 Jul 30. pii: S0168-8278(16)30403.
    PubMed     Text format     Abstract available


    May 2016
  280. VERKADE HJ, Bezerra JA, Davenport M, Schreiber RA, et al
    Biliary atresia and other cholestatic childhood diseases: advances and future challenges.
    J Hepatol. 2016 May 6. pii: S0168-8278(16)30186.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Liver Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: